[HTML][HTML] Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel… - … England Journal of …, 2018 - Mass Medical Soc
Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …
prolonged progression-free survival, as compared with placebo, among patients with stage …
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
SJ Antonia, A Villegas, D Daniel, D Vicente… - The New England …, 2018 - europepmc.org
Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …
prolonged progression-free survival, as compared with placebo, among patients with stage …
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente… - 2018 - christie.openrepository.com
BACKGROUND: An earlier analysis in this phase 3 trial showed that durvalumab
significantly prolonged progression-free survival, as compared with placebo, among patients …
significantly prolonged progression-free survival, as compared with placebo, among patients …
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente… - dev.az-brands.com
METHODS We randomly assigned patients, in a 2: 1 ratio, to receive durvalumab
intravenously, at a dose of 10 mg per kilogram of body weight, or matching placebo every 2 …
intravenously, at a dose of 10 mg per kilogram of body weight, or matching placebo every 2 …
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
PACIFIC Investigators - New England Journal of …, 2018 - yonsei.elsevierpure.com
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …
prolonged progression-free survival, as compared with placebo, among patients with stage …
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
PACIFIC Investigators - New England Journal of …, 2018 - vivantes.elsevierpure.com
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …
prolonged progression-free survival, as compared with placebo, among patients with stage …
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente… - New England Journal …, 2018 - hub.hku.hk
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …
prolonged progression-free survival, as compared with placebo, among patients with stage …
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
SJ Antonia, A Villegas, D Daniel, D Vicente… - New England Journal …, 2018 - orbi.uliege.be
BACKGROUND: An earlier analysis in this phase 3 trial showed that durvalumab
significantly prolonged progression-free survival, as compared with placebo, among patients …
significantly prolonged progression-free survival, as compared with placebo, among patients …
[引用][C] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
SJ Antonia, A Villegas, D Daniel, D Vicente… - 2018 - repository.ubn.ru.nl
BACKGROUND: An earlier analysis in this phase 3 trial showed that durvalumab
significantly prolonged progression-free survival, as compared with placebo, among patients …
significantly prolonged progression-free survival, as compared with placebo, among patients …
[PDF][PDF] Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente… - 2018 - pure.manchester.ac.uk
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …
prolonged progression-free survival, as compared with placebo, among patients with stage …